September is dedicated to recognizing and spreading awareness of Childhood, Blood, Ovarian & Prostate Cancers. This month, we honor all of those who have been affected by these types of cancers as we continue our work to transform cancer care.

New research in non-small cell lung cancer sought to describe the genomic & treatment landscape of on & off-target ALK resistance mutations detected by comprehensive genomic profiling (CGP). Click for more details & the results of this #ESMO24 data: foundationmedicine.com/research/esmo-…

New #data being presented at #ESMO24 features research utilizing Foundation Medicine’s homologous recombination deficiency signature (HRDsig) in endometrial cancer. Read through the abstract and study highlights at the link here: spkl.io/6010f8pl2

Proud to see this new #research at #ESMO24 being presented as part of the Presidential Symposium III: Eyes to the future. Click the link below to learn more: spkl.io/6018fEax6